Who We Are

PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.
Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need. We have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.

South Asian Association for Regional Co-operation (SAARC) includes 8 countries; India, Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan and Sri Lanka, these countries not only share geographical proximity and political agenda but also share many common social concerns- Healthcare, Education, Economic Infrastructure and many more. SAARC region share similar challenges when it comes to awareness, accessibility, availability and affordability of safe plasma products because of the limited consistent supply of safe plasma and low plasma fractionation capacity.

We therefore pursue a vision of ushering in the Plasma Protein industry in SAARC region & endeavor to provide an extensive assortment of safe plasma products to enrich the quality of life of patients. This is a step working towards addressing the very contemporary concept of regional self sufficiency.

PlasmaGen BioSciences, having a niche and expertise in the cosmos of plasma product therapies; also works closely with the government on various plasma policies and haemovigilance, which can be extended and leveraged for growth of this industry in entire SAARC region.

Our Story

PlasmaGen BioSciences was established in the year 2010 on September 7th.

PlasmaGen realizes a huge gap that exists between the availability of plasma products and the requisite of its therapies in Asia. As a matter of fact Asia seems to hold about 60% of the world’s population, but in terms of global plasma fractionation capacity it merely accounts for about 20% - a huge imbalance.

India with 1.32 Billion people, accounts for almost 18% of the global population. The access to healthcare services is quite challenging, as the affordability varies to a great degree. It collects about 10 million units of blood units every year and componentizes only 40 % of it. Therefore domestically plasma availability is very low and so is the case with fractionation capacity.

In terms of Self Sufficiency Ratio (SSR); India stands at 35-40% where consumption rates for two important plasma proteins- Albumin and IVIG, far surpass the rates of production, thereby making establishment of a plasma products company not just a scientific necessity but also an Indispensable socio-economic obligation.

Sept 7th – Our Journey begins……

The day when PlasmaGen BioSciences laid down its foundation stone. And there lied the “Genesis” of India’s first Plasma Protein Therapeutics focused company.

Journey Start
Journey Start
2011

Starts buildingup team and makes its first international representation at the Plasma Product Biotechnology (PPB) meet in Cyprus.

Launches its first product in the Indian market, ‘RonsenGlob’ - Intravenous Immunoglobulin.

In the same year, it launches its pipeline product ‘PlasmaHep’ – Hepatitis B Immunoglobulin, which in the Indian scenario was an imperative addition propelling the prophylactic prevention of Hepatitis B.

Participates in a global event in the World Health Organization (WHO) to discuss “Plasma Product Scenario in India.

Becomes one of the very few biopharmaceutical companies in India to obtain the license for Plasma Collection from various blood banks of India & production of plasma products from the Regulatory Authorities of India

Conceptualized, and was instrumental in Organizing, Planning & Execution of the 1st BioplasmaWorld Asia Conference held in Hong Kong.

Actively participated in developing and execution of Haemovigilance Program in India.

Journey Start
Journey Start
2013

PlasmaGen launched its double viral inactivated Intravenous Immunoglobulin under its brand name ‘PlasmaGlob’.

Later in 2013, understanding the need of Albumin in India, PlasmaGen launched ‘AlbuMax’- 20% Albumin solution. The product gained immediate acceptance.

PGB’s active contribution at IXth Annual Conference of South Asian Association of Transfusion Medicine, Gurgaon, New Delhi.

Very actively participated in conceptualization and formulation of country’s National Policy for Access to Plasma Derived Medicinal Products from Human Plasma for Clinical / Therapeutic Use

With a vision to provide Indian patients with the maximum range of Plasma Products, PlasmaGen launched two major hyperimmunes- ‘PlasmaRho-I.M.’ – Anti-D Immunoglobulin for Rh incompatibility & maternal sensitization and ‘PlasmaRab’ – Anti Rabies Immunoglobulin for the rabies prophylaxis.

Journey Start
Journey Start
2015

Worked with Indian pharmacopoeia in formulating the plasma product monograph.

Worked with National Pharmaceutical Pricing Authority towards rationalizing the price of Plasma products

Launch of Verbumin - additional variant of Albumin to be able to meet the increasing need of albumin in the country.

Launch of PlasmaRho-D I.V. with an intent to cater to patients with a therapy that entails at par efficacy and higher affordability.

Participated in State of Art Multiple Myeloma conference held in Chandigarh.

Hosted an international Symposium on the topic “Realizing the potential of Anti-D I.V. in Haematology” at Haematocon conference held in Jaipur.

Journey Start